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Introduction
Osteoarthritis (OA) is the joint disease with the highest 
incidence. Th e disease is in general divided into primary 
OA and secondary OA. Primary OA has no obvious 
trigger, while secondary OA is the result of an evident 
underlying aﬄ  iction. Th e main features of this disease are 
cartilage erosion, synovial ﬁ brosis, osteophyte formation 
at the joint margins and sclerosis of the subchondral 
bone. Patients with OA suﬀ er from joint pain and tender-
ness, occasional eﬀ usions and, in the long run, loss of 
joint function.
Th e etiology of primary OA is not known but several 
risk factors have been detected. Systemic risk factors 
include genetic background, ethnicity, gender and obesity, 
but the main risk factor for the initiation and progression 
of primary OA is ageing. Functional articular cartilage is 
maintained by the cartilage cells, chondrocytes. Changes 
in chondrocytes, leading to the inability of these cells to 
maintain the homeostasis of articular cartilage, can be 
expected to be at the root of OA development. In view of 
the fact that the principal risk factor of OA is ageing, age-
related changes in chondrocytes are likely to be involved 
in OA development.
Changes in osteoarthritic chondrocytes
Cartilage is, on a weight basis, mainly composed of colla-
gens and proteoglycans. Collagens – for the most part type 
II, type IX and type XI – provide tensile strength, while the 
proteoglycan aggrecan retains water in the matrix. In 
humans, cartilage is composed of three zones: superﬁ cial 
zone, middle zone and deep zone. Th e superﬁ cial zone 
contains disc-shaped chondrocytes, the cells in the middle 
zone cells are more spherical and the deep zone contains 
spherical chondrocytes arranged in columns.
Cartilage damage in OA has several characteristics. At 
the initial stages of OA the cartilage surface is intact but 
focal edema and minor ﬁ brillations can be observed. 
Subse quently the superﬁ cial zone becomes ﬁ brillated 
and chondrocytes are lost from this zone. Finally, 
ﬁ brillations progress into ﬁ ssures – a process that is 
followed by cartilage erosion, denudation of bone and 
joint deformation.
At the initial stages of OA, chondrocytes start to 
multiply and form multicellular clusters. In addition, 
chondro cytes expressing markers of hypertrophic 
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chondro cytes are found in OA cartilage. A subpopulation 
of OA chondrocytes synthesizes molecules that, under 
normal conditions, are only expressed by terminally 
diﬀ er entiated (hypertrophic) chondrocytes, normally 
found in growth plates. Expression of osteocalcin, alka-
line phosphatase, c-maf, Runx2 and type X collagen has 
been demonstrated in OA chondrocytes [1-5]. Moreover, 
chondrocytes in OA cartilage express high levels of 
matrix metalloproteinase 13 (MMP-13), the enzyme 
most potently degrading type II collagen [6]. Th is under-
scores the hypertrophy-like character of OA chondro cytes 
since MMP-13 is highly upregulated during chondrocyte 
terminal diﬀ erentiation, and deﬁ ciency of MMP-13 even 
results in impaired endochondral ossiﬁ cation [7,8].
During OA, cartilage matrix degradation exceeds 
matrix deposition resulting in net matrix loss. In contrast 
to what is observed in inﬂ ammatory arthritis, mRNA 
expression and synthesis of a number of matrix molecules 
is increased instead of decreased compared with normal 
cartilage [9,10]. Only in the very late stages of OA does 
synthesis of matrix molecules drop below control levels. 
Th e synthesis of the main structural component of carti-
lage, type II collagen, is clearly enhanced in OA cartilage 
[11,12]. In OA cartilage, both catabolism (for example, 
MMP-13 synthesis) and anabolism (type II collagen 
synthesis) are high. It is unclear whether elevated 
catabolism and enhanced anabolism is achieved by the 
same cells or by diﬀ erent chondrocyte subpopulations.
Catabolic cytokines
Catabolic cytokines have been suggested to play a 
dominant role in OA. Chondrocytes can be stimulated by 
catabolic cytokines to release cartilage degradation 
products, ultimately leading to damage. A cytokine that 
is suggested to be a principle mediator of joint damage in 
OA is IL-1. Chondrocytes from OA cartilage display high 
levels of IL-1α and IL-1β and have elevated expression of 
the plasma membrane-bound IL-1 receptor I, while the 
decoy IL-1 receptor II is downregulated in OA chondro-
cytes [13]. Not only do ﬁ brillated areas show these 
expression patterns, but also cartilage proximal to 
macroscopic OA lesions demon strates a higher binding 
of TNFα and IL-1β com pared with chondrocytes from 
morphologically normal cartilage in the same joint [14]. 
Th is indicates not only that the levels of IL-1 are 
increased in OA joints, but also that OA chondro cytes 
are more sensitive to IL-1.
IL-1 is considered a principle mediator of joint damage 
in OA. IL-1 has the ability to stimulate chondrocytes to 
degrade both aggrecan and collagen [15]. Th is cytokine 
causes destruction of cartilage by increasing enzyme 
activity while decreasing the synthesis of enzyme inhibi-
tors [16]. IL-1 can stimulate chondrocytes to produce nitric 
oxide [17], matrix metalloproteinases [18] and aggrecanases 
(ADAMTS) [19], and suppresses the synthesis of aggrecan 
and collagen type II [20-22].
Th e latter is remarkable if IL-1 plays a dominant role in 
OA pathophysiology. IL-1 is a potent inhibitor of chondro-
cyte type II collagen synthesis, but type II collagen 
synthesis is increased during OA as discussed above. Th is 
discrepancy points to alternative players that are involved 
in OA. IL-1 might play a role in the induction of enzyme 
expression but is unlikely to be the only factor that deter-
mines development and progression of OA.
Osteoarthritic chondrocytes also express, besides cata-
bolic factors, anabolic factors such as transforming 
growth factor beta (TGFβ) [23,24]. Increased synthetic 
activity in early OA has been found to be accompanied 
with an upregulation of TGFβ expression [25,26]. We 
propose a role for TGFβ not only as a cartilage protective 
agent but also as a mediator of cartilage degeneration 
during ageing and OA development.
Transforming growth factor beta
Th e TGFβ superfamily is composed of over 35 members. 
Th e family members play fundamental roles in develop-
ment and homeostasis. In mammals, three isotypes of 
TGFβ are found: β1, β2 and β3. Expression of these three 
isoforms is diﬀ erently regulated at the transcriptional 
level due to dissimilar promoter sequences [27].
TGFβ is secreted as an inactive complex and requires 
activation before it is able to bind to its receptor [28]. 
Activated TGFβ binds to the TGFβ type II receptor and 
forms a complex that recruits the TGFβ type I receptor, 
ALK5. TGFβ has also recently been shown, however, to 
have the ability to signal via the alternative TGFβ type I 
receptor ALK1 in chondrocytes. In endothelial cells, but 
also in chondro cytes, activation of the ALK5 route is 
followed by Smad2 or Smad3 phosphorylation while 
ALK1 has been found to result in phosphorylation of 
Smad1, Smad5, or Smad8 [29-31]. Th e activated 
receptor Smads form a complex with the co-Smad, 
Smad4 – this complex translocates to the nucleus and 
modiﬁ es gene expression. Interestingly, signaling via 
either ALK5 or ALK1 can determine the response of 
cells to TGFβ stimulation, which can be totally contrary 
[32,33]. For example, in endothelial cells ALK5 inhibits 
migration whereas ALK1 stimulates migration and 
proliferation [34].
Signaling via the Smad pathway appears to be the most 
important signaling pathway for TGFβ, but this is not the 
only pathway. Mitogen-activated protein kinase, Rho-like 
GTPase and phopshatidylinositol-3-kinase pathways are 
involved in TGFβ signaling (reviewed in [35]). Activation 
of TGFβ activated kinase 1 occurs independent of ALK5 
kinase activity and results in P38 and JNK signaling [36]. 
Th at TGFβ activates diﬀ erent pathways calls attention to 
the fact that one has to take into account the diﬀ erences 
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in management of the TGFβ signal in diﬀ erent cell types 
and the subsequent variation in TGFβ eﬀ ects.
Transforming growth factor beta and osteoarthritis
Family studies have indicated a relation between TGFβ 
and a disease related to OA. In Japanese women a poly-
morphism of TGFβ1 on position 29 (T to C, amino acid 10) 
positioned in the signal sequence region of TGFβ1 is 
related to an elevated prevalence of spinal osteophytosis and 
ossiﬁ cation of the posterior longitudinal ligament [37,38].
Asporin inhibits TGFβ-mediated expression of cartilage 
matrix genes such as collagen type II and aggrecan, and 
inhibits accumulation of proteoglycan [39]. Kizawa and 
colleagues found an asporin polymorphism that showed 
a signiﬁ cantly higher frequency in OA [39]. Th e D-14 
polymorphism had a stronger inhibitory eﬀ ect on TGFβ 
than the common D-13 repeat. Th is indicates that 
expression of D-14 results in strong TGFβ inhibition and 
that this is associated with OA development. When this 
study was repeated in a Spanish Caucasian population by 
Rodriguez-Lopez and colleagues, however, the higher 
susceptibility to OA of people with the D-14 polymor-
phism was not found [40]. In a subset of UK Caucasians, 
a trend was seen towards a higher degree of D-14 poly-
morphism in OA. In a diﬀ erent ethnic group of Asian 
origin, Han Chinese, the OA susceptibility was again 
found [41]. Th ese studies indicate that reduced TGFβ 
signal ing can result in OA development.
Mice deﬁ cient for Smad3 developed degenerative joint 
disease resembling human OA. Chondrocytes present in 
the articular cartilage of Smad3-deﬁ cient mice showed 
enhanced chondrocyte hypertrophy indicated by increased 
expression of type X collagen. Th ese data indicate that 
Smad3 signaling is essential for repressing chondrocyte 
terminal diﬀ erentiation. Th is observation is supported by 
studies in mice that overexpress a dominant-negative 
TGFβ type II receptor in skeletal tissues [42]. Th ese mice 
developed progressive skeletal degeneration that strongly 
resembles human OA. In addition, mice that lack latent 
TGFβ binding protein 3 also show altered chondrocyte 
diﬀ erentiation and early OA development [43,44]. 
Interference with normal TGFβ signaling apparently 
results in aberrations in chondrocyte diﬀ erentiation and 
enhanced OA develop ment.
Th e eﬀ ects of TGFβ on chondrocytes seem to be 
context related. Serum factors can modulate the eﬀ ect of 
TGFβ on chondrocyte proliferation. Growth of cultured 
rabbit chondrocytes decreased after TGFβ stimulation in 
the presence of a low serum concentration, while the cell 
number increased in the presence of high serum levels 
[45,46]. Th e rabbit chondrocytes demonstrated diﬀ er-
ences in TGFβ receptor expression as a function of cell 
cycle progression [47-49]. Moreover, expression of TGFβ 
receptors appeared to be changed by nitric oxide and 
ROS levels and OA chondrocytes became insensitive to 
TGFβ, which was concomitant with loss of the expression 
of TGFβ type II receptor on these chondrocytes [50,51]. 
A loss of the TGFβ type II receptor has also been 
observed by our own group during ageing and OA in 
murine models [52,53]. Moreover, proteoglycan synthesis 
is also diﬀ erentially regulated by TGFβ in rabbit and 
bovine chondrocytes depending on the diﬀ erentiation 
stage of the chondrocytes [54,55]. In calf cartilage 
explants, proteoglycan synthesis is stimulated by TGFβ in 
a dose-dependent manner [56,57]. From these obser va-
tions it can be concluded that, in general, TGFβ maintains 
chondrocyte and cartilage homeostasis but that changes 
in diﬀ erentiation stage and associated alterations in 
receptor expression modify the eﬀ ect of TGFβ on 
chondrocyte function.
We have shown in young mice that TGFβ has favorable 
eﬀ ects on cartilage, such as stimulation of proteoglycan 
synthesis in cartilage [58]. In old mice, however, stimu-
lation of aggrecan synthesis by TGFβ is reduced – and 
this is associated with a loss in ALK5 expression, and 
TGFβ type II receptor expression, on articular chondro-
cytes [59]. Livne and colleagues showed in mandibular 
chondrocytes a strong age-related decrease in stimulation 
of proteo glycan synthesis by TGFβ in young mice 
(1 month old, +120%) and old mice (18 months old, +7%) 
[59,60]. Nonchondrocytic cells have also been shown to 
display a diminished response to TGFβ during ageing. 
Smooth muscle cells derived from old rats produce 
normal levels of TGFβ but fail to respond to the 
inhibitory eﬀ ects of this growth factor in contrast to 
young cells [61]. Th e response to TGFβ appears to be age 
related and a change in TGFβ signaling can play a role in 
age-related diseases such as OA.
Control of chondrocyte diff erentiation by SMADs
Activation of the Smad1/5/8 route in chondrocytes is 
strongly associated with chondrocyte terminal diﬀ eren-
tiation and hypertrophy [62]. Bone morphogenetic protein 
itself or activation of the bone morphogenetic protein 
pathway (Smad1/5/8) leads, both in the growth plate and 
in articular chondrocytes, to expression of terminal 
diﬀ er entiation markers [63-65]. Signaling via Smad1 
cooperates with the transcription factor Runx2 (CBFA1) 
to induce chondrocyte terminal diﬀ erentiation. Th is 
cross-talk between the bone morphogenetic protein-
associated Smads and Runx2 is essential to stimulate the 
expression of hypertrophy markers in diﬀ erentiating 
chondrocytes [66]. Blocking the Smad1/5/8 route by 
overexpression of Smad6 reduced the expression of both 
type X collagen and alkaline phosphatase activity in 
chondro cytes, while using Smad6 antisense had an 
opposite eﬀ ect [67]. Moreover, in vivo inhibition of 
Smad1/5/8 phosphory lation, as observed in Smad6 
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transgenic mice, was associated with delayed chondro-
cyte hypertrophy [68]. In articular chondrocytes treated 
with azacytidine, reduced Smad2 and Smad3 expression 
and signaling and increased Smad1/5 expression 
correlated with elevated synthesis of type X collagen and 
alkaline phosphatase. Th ese observations clearly demon-
strate that terminal diﬀ erentiation of articular chondro-
cytes is associated with dominant signaling via the 
Smad1/5/8 pathway [69].
Th e latter observation shows not only that activation of 
the Smad1/5/8 route leads to terminal diﬀ erentiation but 
also that loss of Smad2/3 can lead to induction of 
chondrocyte terminal diﬀ erentiation. Th e inhibitory 
eﬀ ects of TGFβ on chondrocyte maturation is mediated 
by the Smad2/3 pathway, as has been shown by 
overexpression of dominant negative Smad2 and Smad3 
in chondrocytes. Mutant mice deﬁ cient for functional 
Smad3 show abnormally increased numbers of type X 
collagen-expressing chondrocytes in articular cartilage. 
Overexpression of both Smad2 and Smad3 blocked 
spontaneous maturation in Smad3-deﬁ cient chondro-
cytes [70,71]. Smad2 and Smad3 are key mediators of the 
inhibitory eﬀ ect of TGFβ on chondrocyte terminal diﬀ er-
entiation [72]. Without Smad2/3 signaling, chondrocytes 
break their quiescent state and undergo anomalous 
terminal diﬀ erentiation. Apparently the balance between 
Smad1/5/8 signaling and Smad2/3 signaling controls 
chondrocyte diﬀ erentiation.
Th e wnt signaling pathways are involved in chondro-
cyte diﬀ erentiation and OA development [73]. Enhanced 
and decreased wnt signaling both result in cartilage loss 
[74,75]. Furthermore, the wnt inhibitor dickkopf1 stimu-
lated chondrocyte apoptosis in OA joints [76]. Increased 
wnt signaling can have a direct eﬀ ect on chondrocyte 
diﬀ erentiation but it can also alter diﬀ erentiation by 
variable modulation of the Smad2/3 and Smad1/5/8 
pathways. wnt signaling leads to inhibition of the activity 
of the GSK3 kinase, which resulted in Xenopus embryos 
in prolonged duration of the Smad1 signal [77]. If a 
similar mechanism takes place in chondrocytes, enhanced 
wnt signaling will result in augmented terminal 
diﬀ er entiation.
Chondrocyte diﬀ erentiation is regulated by Sox9, and 
additional Sox molecules, but chondrocyte terminal 
diﬀ erentiation is rigorously controlled by the transcrip-
tion factor Runx2 [78,79]. Mice lacking Runx2 do not 
show chondrocyte terminal diﬀ erentiation, and bone 
formation via this pathway is totally blocked [80]. Smad 
pathways are integrated via Runx2 to control chondrocyte 
terminal diﬀ er entiation. Interaction of Runx2 with 
Smad1 facili tates the function of Runx2 in stimulating 
terminal diﬀ erentiation, while Smad3 blocks Runx2 
function [81-83]. Th e Smad2/3 and Smad1/5/8 balance 
controls the Runx2 function and terminal diﬀ erentiation.
Change in transforming growth factor beta 
signaling in ageing chondrocytes and osteoarthritis
We have demonstrated an age-related loss of TGFβ type I 
receptor ALK5 and phosphorylation of Smad2/3 in 
murine articular cartilage [84]. Expression of non phos-
phorylated Smad2 was not altered during ageing. 
Moreover, in two experimental models of OA – the 
DMM (meniscus destabilization) model and STR/ORT 
mice (spontaneous OA) – development of the disease 
was correlated with a loss of ALK5 expression. Expression 
of the alternative TGFβ receptor, ALK1, did not decrease 
to a similar extent as ALK5 [85]. As a result, the ratio of 
ALK1/ALK5 expressing cells strongly increased in OA 
articular chondrocytes. During ageing of C57Bl mice, the 
ratio ALK1/ALK5 increased up to sixfold. In the DMM 
model, OA develops on the medial tibial side while the 
lateral side is relatively protected. A more than threefold 
increase in the ALK1/ALK5 ratio was observed on the 
medial side while the ratio on the lateral side was 
unaﬀ ected. STR/ORT mice develop OA starting at the 
medial tibia from an age of 2 to 3 months. Th e ALK1/
ALK5 ratio was 5 on the medial tibia at an age of 3 
months and was 18 in 1-year-old animals. Th e lateral 
tibia showed a ratio increase from 1 to 5 in the same 
period. Clearly an increased ALK1/ALK5 ratio in 
chondrocytes is associated with ageing and OA 
development [85].
We postulate that the loss of ALK5 expression and the 
concomitant elevated ratio of ALK1/ALK5 will have 
profound eﬀ ects on chondrocyte behavior. Th e eﬀ ect of 
TGFβ on chondrocytes will be governed by the ALK1/
ALK5 ratio. A prevailing expression of ALK5 will result 
in a dominance of the Smad2/3 signaling route, while 
ALK1 dominance will result in a stronger Smad1/5/8 
pathway. Th e balance of these routes has been shown to 
control chondrocyte diﬀ erentiation (see above).
We and others have shown that TGFβ signals in 
chondro cytes not only via ALK5 but also via ALK1 [86]. 
Exposure of chondrocytes to TGFβ results in both 
Smad2/3 and Smad1/5/8 phosphorylation within 15 to 30 
minutes [85]. In addition, overexpression of constitutive 
active ALK5 (Smad2/3) results in increased expression of 
aggrecan while constitutive ALK1 (Smad1/5/8) expres-
sion leads to elevated expression of MMP-13. Blocking 
ALK5 expression using siRNA resulted in elevated 
expression of MMP-13 [85]. Th e ALK1 (Smad1/5/8) and 
ALK5 (Smad3) signaling balance in chondrocytes 
apparently determines MMP-13 expression. In addition, 
a clear trend towards elevated type II collagen and 
aggrecan expression was observed in cells with constitu-
tive active ALK1. Noticeably, human osteoarthritic 
cartilage demonstrated a signiﬁ cant correlation between 
ALK1 and MMP-13 mRNA expression and a trend 
(P  =  0.05 to 0.1) with type II collagen and aggrecan 
van der Kraan et al. Arthritis Research & Therapy 2010, 12:201 
http://arthritis-research.com/content/12/1/201
Page 4 of 9
expression. Th ese observations indicate that ALK1 signal-
ing can induce a chondrocyte phenotype similar to that 
found in OA cartilage, a phenotype with simultaneous 
enhanced expression of matrix molecules and MMP-13.
We hypothesize that articular chondrocytes reside in a 
quiescent state in young healthy cartilage due to the 
inhibitory eﬀ ect of TGFβ, via Smad2/3, on the progres-
sion of chondrocyte diﬀ erentiation. During ageing of 
chondro cytes and OA development, signaling through 
ALK1 and Smad1/5/8 is increased in favor of signaling 
via ALK5 and Smad2/3. Th e dominant Smad1/5/8 
signaling triggers the articular chondrocytes to leave their 
quies cent state (Figure  1). Th is leads to a chondrocyte 
phenotype with characteristics analogous to terminal 
diﬀ erentiated growth plate chondrocytes – a chondrocyte 
with an autolytic phenotype typiﬁ ed by degradation of its 
surrounding cartilage matrix, as can be found in OA 
cartilage.
Th is hypothesis can explain the often enigmatic eﬀ ects 
of TGFβ on articular cartilage. Th e eﬀ ect of TGFβ on 
chondrocytes will be determined by the relative expres-
sion of ALK5 and ALK1. In general, we have observed in 
young animals that TGFβ is protective for articular 
cartilage [84,87-90]. Prolonged exposure of cartilage to 
high TGFβ levels, however, induces osteoarthritic lesions 
in murine knee joints, starting in the deep zones [91]. We 
have observed that the chondrocytes in the deep zone, 
just above the tidemark, show high ALK1 expression 
(personal observation). In old animals, showing a 
decrease in the ALK5/ALK1 ratio, the protective eﬀ ect of 
TGFβ is lost and TGFβ can act as an OA-inducing factor 
[85,92,93] (Table 1).
In conclusion, loss of the Smad2/3 signaling and 
relatively enhanced Smad1/5/8 signaling can explain the 
enigmatic observation in OA cartilage of elevated 
expression of both matrix molecules and proteolytic 
enzymes, like MMP-13. Moreover, the age-related loss of 
ALK5 signaling in chondrocytes can give a clue to the 
high correlation between ageing and OA development. 
Interestingly, a remarkable relationship has been reported 
between reduced TGFβ signaling and another, highly age-
related aﬄ  iction, Alzheimer’s disease [94,95]. Alzheimer’s 
disease is characterized by progressive neurodegeneration 
and cerebral accumulation of the β-amyloid peptide. 
Reduced TGFβ type II receptor expres sion and signaling 
has been demonstrated in Alzheimer’s disease. Over-
expression of dominant negative Smad3 causes neuro-
degeneration in cell cultures, indicat ing that loss of 
Figure 1. Alterations in transforming growth factor beta signaling cause changes in chondrocyte diff erentiation and osteoarthritis 
development. Transforming growth factor beta (TGFβ) can either signal by the Smad2/3 route (canonical) or the Smad1/5/8 route. Smad2/3 and 
Smad1/5/8 form a complex with Smad4 that enters the nucleus and modulates gene expression and Runx2 function. The signaling by Smad2/3 
and Smad1/5/8 is diff erentially modifi ed by a number of intracellular molecules. Both Smad routes are blocked by Smad7, while Smad6 blocks 
preferentially the Smad1/5/8 pathway [100,101]. wnt signaling modifi es these pathways by stabilization of Smad1/5/8 [102]. Smurf1 and Smurf2 
are E3 ubiquitin ligases that inhibit Smad signaling. Smurf1 triggers the degradation of Smad1/5/8 while Smurf2 stimulates mainly the degradation 
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Smad2/3 signaling is involved. Reducing neuronal TGFβ 
signaling via the Smad2/3 pathway in mice resulted in age-
dependent neurodegeneration. Th ese ﬁ ndings show that 
reduced TGFβ Smad3-dependent signaling in neuronal 
cells increases age-dependent neuro degeneration and 
Alzheimer’s disease-like symp toms. Th is observation 
points to a striking similarity between authentic Alzheimer’s 
disease and Alzheimer’s disease of the joint – OA.
Targets for therapy
We postulate that the OA process is driven by the loss of 
the Smad2/3 block on diﬀ erentiation in articular 
chondrocytes, leading to progression of chondrocyte 
diﬀ erentiation and an autolytic phenotype. In the early 
stages of OA – bearing in mind that OA is initially a focal 
process – not all chondrocytes will be at the same stage 
of diﬀ erentiation. A mixture of cell populations will be 
present in OA cartilage. Some chondrocytes will have 
progressed in their diﬀ erentiation to an OA chondrocyte 
phenotype, triggered by a loss of the Smad2/3 block. 
Other cells will still be in a quiescent, healthy state of 
diﬀ erentiation. Th e latter cells can be targets for therapy 
to block further progression of the OA process. Blocking 
the progression of chondrocyte diﬀ erentiation will block 
further expansion of the OA process in remaining healthy 
cartilage.
Loss of Smad2/3 signaling is at the root of the OA 
process in our view. To inhibit articular chondrocytes in 
their deviant diﬀ erentiation, this pathway has to be 
stimulated at the same time as circumventing the role of 
the ALK1 receptor. Compounds speciﬁ cally stimulating 
the Smad2/3 route should be developed. A similar 
strategy, using TGFβ mimetics, has been proposed to 
treat Alzheimer’s disease [96]. TGFβ mimetics have 
already been developed that can mimic TGFβ eﬀ ects on 
cells [97].
An alternative therapy could be stimulation of one of 
the other Smad2/3 routes in chondrocytes. Signaling via 
the activin ALK4 and ALK7 receptors leads to activation 
of the Smad2/3 pathway [98]. Little is known about the 
expression of these receptors in old chondrocytes, but 
potentially these receptors could be targets to enhance 
Smad2/3 signaling in chondrocytes in OA.
An alternative strategy would be blocking ALK1 or the 
Smad1/5/8 pathway in chondrocytes to block the trigger 
that stimulates progression of chondrocyte diﬀ erentia-
tion. Since ALK1 is involved in vessel formation, blocking 
ALK1 can interfere with this process [99]. As blockers of 
ALK1 to treat OA will be mainly applied in middle-aged 
and older people, additional eﬀ ects of this treatment are 
expected to be limited. General blocking of the 
Smad1/5/8 pathway using kinase blockers that inhibit the 
activity of ALK1, ALK2, ALK3 and ALK6 is an alternative 
option to stop chondro cyte aberrant diﬀ erentiation.
Th e potential side eﬀ ects of the above therapies are 
unclear. Eﬀ ects on growth plate chondrocytes will be absent 
since the growth plates are not present in elderly humans. 
Th e eﬀ ects of stimulating the Smad2/3 pathway using TGFβ 
mimetics or the ALK4/7 pathway could result in side eﬀ ects, 
such as induction of ﬁ brosis. Block ing ALK1 will have few 
side eﬀ ects due to the restricted eﬀ ect of ALK1 in vessel 
formation, which is anticipated to be relatively unimportant 
in elderly people. Th e eﬀ ects of general inhibition of the 
Smad1/5/8 pathway in elderly people are hard to predict but 
this might interfere with bone metabolism. Bone 
morphogenetic protein signaling is known to be involved in 
both bone formation and bone degradation, the latter by 
stimulation of osteoclast maturation.
Table 1. Arguments implying a role for alterations in TGFβ signaling in osteoarthritis development
Genetic studies point to a role for TGFβ in osteoarthritis
Mice that express a dominant negative TGFβ type II receptor in skeletal tissues showed enhanced chondrocyte hypertrophy and osteoarthritis
Mice defi cient for Smad3 or latent TGFβ binding protein 3 demonstrated enhanced chondrocyte hypertrophy and osteoarthritis
Cartilage protective eff ects of TGFβ are lost in ageing mice
ALK1/ALK5 expression ratio is increased in cartilage in ageing mice and experimental osteoarthritis
ALK1 overexpression results in MMP-13 upregulation in chondrocytes
Blocking ALK5 expression, using siRNA, leads to elevated expression of MMP-13
In human osteoarthritis cartilage, ALK1 expression and MMP-13 expression signifi cantly correlate
Smad2/3 signaling inhibits, while Smad1/5/8 signaling stimulates, progression of chondrocyte diff erentiation 
In osteoarthritis, synthesis of matrix molecules (type II collagen) is increased – indicating no dominant role for catabolic cytokines
Alterations in TGFβ signaling in osteoarthritis can provide an explanation for the enigmatic observation of concomitant increased synthesis of matrix molecules 
(type II collagen) and increased MMP-13 production
MMP-13, matrix metalloproteinase 13; TGFβ, transforming growth factor beta.
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Conclusion
Until now no eﬀ ective therapy has been developed for 
OA that interferes with disease progression. Painkilling 
and joint replacement are the only options at this 
moment. Th e proposed treatment attacks the OA process 
at its core, blocking the generation of chondrocytes with 
an autolytic phenotype. Th e proposed OA mechanism 
and potential therapies open the venue to new strategies 
to treat this common crippling joint disease.
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